midazolam has been researched along with Depression in 22 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation." | 9.69 | A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. ( Bai, YM; Chen, LF; Chen, MH; Li, CT; Li, WC; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " However, whether low-dose ketamine infusion alters klotho levels among patients with treatment-resistant depression (TRD) remains unknown." | 9.69 | Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " This trial will provide efficacy, safety and health economic data on serial ketamine infusions and thus help inform clinical practice on the potential role of this treatment in the management of depression." | 9.69 | Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]). ( Igoe, A; Jelovac, A; Loughran, O; McCaffrey, C; McDonagh, K; McDonogh, S; McLoughlin, DM; Mohamed, E; O'Neill, C; Shackleton, E; Shanahan, E; Terao, M; Whooley, E, 2023) |
| "Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major depressive disorder (MDD) and clinically significant suicidal ideation examined changes in factor analysis-derived symptom clusters from standard measures of depression (Hamilton Depression Rating Scale, HDRS; Beck Depression Inventory, BDI) and mood disturbance (Profile of Mood States, POMS), and their relationship to severity of suicidal ideation (Beck Scale for Suicidal Ideation; SSI)." | 9.51 | Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression. ( Burke, AK; Grunebaum, MF; Hochschild, A; Keilp, JG; Madden, SP; Mann, JJ, 2022) |
| "This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer." | 9.24 | Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. ( Fan, W; Li, G; Liu, Y; Sun, Y; Yang, H; Zhang, J; Zheng, Y, 2017) |
| "To assess and compare the impact of overnight sedation with midazolam or propofol on anxiety and depression levels, as well as sleep quality, in non-intubated patients in intensive care." | 9.08 | Overnight sedation with midazolam or propofol in the ICU: effects on sleep quality, anxiety and depression. ( Borgeat, A; Fuchs-Buder, T; Gachoud, JP; Suter, PM; Treggiari-Venzi, M, 1996) |
| " These findings may help explain the more modest findings in clinical IV ketamine trials for suicidal ideation than overall depression." | 8.12 | A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. ( Ballard, ED; Bloomfield-Clagett, B; Fava, M; Greenstein, DK; Grunebaum, MF; Mathew, SJ; Murrough, JW; Phillips, JL; Sanacora, G; Wilkinson, ST; Zarate, CA, 2022) |
| "The benefits of low-dose ketamine for patients with treatment-resistant depression (TRD) and prominent suicidal ideation require further investigation." | 5.69 | A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation. ( Bai, YM; Chen, LF; Chen, MH; Li, CT; Li, WC; Lin, WC; Mao, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " Eighty-two patients with self-reported dental anxiety either completed treatment with dentist-administered cognitive behavioural therapy (D-CBT, n = 36), or received dental treatment while sedated with midazolam combined with the systemized communication technique "The Four Habits Model" (Four Habits/midazolam, n = 41)." | 5.69 | Changes in symptoms of anxiety, depression, and PTSD in an RCT-study of dentist-administered treatment of dental anxiety. ( Hauge, MS; Stora, B; Willumsen, T, 2023) |
| " However, whether low-dose ketamine infusion alters klotho levels among patients with treatment-resistant depression (TRD) remains unknown." | 5.69 | Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation. ( Bai, YM; Chen, MH; Li, CT; Lin, WC; Su, TP; Tsai, SJ; Tu, PC; Wu, HJ, 2023) |
| " This trial will provide efficacy, safety and health economic data on serial ketamine infusions and thus help inform clinical practice on the potential role of this treatment in the management of depression." | 5.69 | Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]). ( Igoe, A; Jelovac, A; Loughran, O; McCaffrey, C; McDonagh, K; McDonogh, S; McLoughlin, DM; Mohamed, E; O'Neill, C; Shackleton, E; Shanahan, E; Terao, M; Whooley, E, 2023) |
| "Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major depressive disorder (MDD) and clinically significant suicidal ideation examined changes in factor analysis-derived symptom clusters from standard measures of depression (Hamilton Depression Rating Scale, HDRS; Beck Depression Inventory, BDI) and mood disturbance (Profile of Mood States, POMS), and their relationship to severity of suicidal ideation (Beck Scale for Suicidal Ideation; SSI)." | 5.51 | Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression. ( Burke, AK; Grunebaum, MF; Hochschild, A; Keilp, JG; Madden, SP; Mann, JJ, 2022) |
| "This study was designed to examine the rapid antidepressant effects of single dose ketamine on suicidal ideation and overall depression level in patients with newly-diagnosed cancer." | 5.24 | Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial. ( Fan, W; Li, G; Liu, Y; Sun, Y; Yang, H; Zhang, J; Zheng, Y, 2017) |
| "To assess and compare the impact of overnight sedation with midazolam or propofol on anxiety and depression levels, as well as sleep quality, in non-intubated patients in intensive care." | 5.08 | Overnight sedation with midazolam or propofol in the ICU: effects on sleep quality, anxiety and depression. ( Borgeat, A; Fuchs-Buder, T; Gachoud, JP; Suter, PM; Treggiari-Venzi, M, 1996) |
| " These findings may help explain the more modest findings in clinical IV ketamine trials for suicidal ideation than overall depression." | 4.12 | A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. ( Ballard, ED; Bloomfield-Clagett, B; Fava, M; Greenstein, DK; Grunebaum, MF; Mathew, SJ; Murrough, JW; Phillips, JL; Sanacora, G; Wilkinson, ST; Zarate, CA, 2022) |
| "The World Health Organization recommends that anxiety, depression, agitation and delirium at end of life should be treated with drugs such as lorazepam, diazepam, midazolam and haloperidol." | 3.83 | Look again at psychedelic drugs. ( Cameron, R, 2016) |
| " Median dosing was 0." | 2.80 | A randomized, double-blind pilot study of dexmedetomidine versus midazolam for intensive care unit sedation: patient recall of their experiences and short-term psychological outcomes. ( Fish, DN; Kiser, TH; Lavelle, JC; MacLaren, R; Malkoski, SP; Mueller, SW; Preslaski, CR, 2015) |
| "Ketamine infusion was associated with significant and rapid reduction in PTSD symptom severity, compared with midazolam, when assessed 24 hours after infusion (mean difference in Impact of Event Scale-Revised score, 12." | 2.79 | Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. ( Aan Het Rot, M; Charney, DS; Feder, A; Iosifescu, D; Kirkwood, K; Lapidus, KA; Morgan, JE; Murrough, JW; Parides, MK; Perez, AM; Saxena, S; Wan, LB, 2014) |
| "Depression is a common mental disorder." | 2.50 | Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression. ( Ke, W; Lihua, P; Su, M; Ziemann-Gimmel, P, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 1 (4.55) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 9 (40.91) | 2.80 |
| Authors | Studies |
|---|---|
| Keilp, JG | 2 |
| Madden, SP | 2 |
| Marver, JE | 1 |
| Frawley, A | 1 |
| Burke, AK | 2 |
| Herzallah, MM | 1 |
| Gluck, M | 1 |
| Mann, JJ | 2 |
| Grunebaum, MF | 3 |
| Hochschild, A | 1 |
| Bloomfield-Clagett, B | 1 |
| Ballard, ED | 1 |
| Greenstein, DK | 1 |
| Wilkinson, ST | 1 |
| Murrough, JW | 2 |
| Mathew, SJ | 1 |
| Phillips, JL | 1 |
| Fava, M | 1 |
| Sanacora, G | 1 |
| Zarate, CA | 1 |
| Lineham, A | 1 |
| Avila-Quintero, VJ | 1 |
| Bloch, MH | 1 |
| Dwyer, J | 1 |
| Su, TP | 2 |
| Li, CT | 2 |
| Lin, WC | 2 |
| Wu, HJ | 2 |
| Tsai, SJ | 2 |
| Bai, YM | 2 |
| Mao, WC | 1 |
| Tu, PC | 2 |
| Chen, LF | 1 |
| Li, WC | 1 |
| Chen, MH | 2 |
| Hauge, MS | 1 |
| Willumsen, T | 1 |
| Stora, B | 1 |
| Jelovac, A | 1 |
| McCaffrey, C | 1 |
| Terao, M | 1 |
| Shanahan, E | 1 |
| Mohamed, E | 1 |
| Whooley, E | 1 |
| McDonagh, K | 1 |
| McDonogh, S | 1 |
| Igoe, A | 1 |
| Loughran, O | 1 |
| Shackleton, E | 1 |
| O'Neill, C | 1 |
| McLoughlin, DM | 1 |
| Parikh, T | 1 |
| Walkup, JT | 1 |
| Nemeroff, CB | 1 |
| He, SF | 1 |
| Ju, WZ | 2 |
| Hu, HB | 1 |
| Zhu, LJ | 1 |
| Zhang, Q | 1 |
| Dai, GL | 2 |
| MacLaren, R | 1 |
| Preslaski, CR | 1 |
| Mueller, SW | 1 |
| Kiser, TH | 1 |
| Fish, DN | 1 |
| Lavelle, JC | 1 |
| Malkoski, SP | 1 |
| Lihua, P | 1 |
| Su, M | 1 |
| Ke, W | 1 |
| Ziemann-Gimmel, P | 1 |
| Feder, A | 1 |
| Parides, MK | 1 |
| Perez, AM | 1 |
| Morgan, JE | 1 |
| Saxena, S | 1 |
| Kirkwood, K | 1 |
| Aan Het Rot, M | 1 |
| Lapidus, KA | 1 |
| Wan, LB | 1 |
| Iosifescu, D | 1 |
| Charney, DS | 1 |
| Ceremuga, TE | 1 |
| Valdivieso, D | 1 |
| Kenner, C | 1 |
| Lucia, A | 1 |
| Lathrop, K | 1 |
| Stailey, O | 1 |
| Bailey, H | 1 |
| Criss, J | 1 |
| Linton, J | 1 |
| Fried, J | 1 |
| Taylor, A | 1 |
| Padron, G | 1 |
| Johnson, AD | 1 |
| Zang, YX | 1 |
| Sun, BT | 1 |
| Zhao, WZ | 1 |
| Rong, N | 1 |
| Tan, HS | 1 |
| Cameron, R | 1 |
| Fan, W | 1 |
| Yang, H | 1 |
| Sun, Y | 1 |
| Zhang, J | 1 |
| Li, G | 1 |
| Zheng, Y | 1 |
| Liu, Y | 1 |
| Strøm, T | 1 |
| Sackey, PV | 1 |
| Martling, CR | 1 |
| Carlswärd, C | 1 |
| Sundin, O | 1 |
| Radell, PJ | 1 |
| Treggiari-Venzi, M | 1 |
| Borgeat, A | 1 |
| Fuchs-Buder, T | 1 |
| Gachoud, JP | 1 |
| Suter, PM | 1 |
| Egan, KJ | 1 |
| Ready, LB | 1 |
| Nessly, M | 1 |
| Greer, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ketamine vs. Midazolam: Testing Rapid Relief of Suicide Risk in Depression[NCT01700829] | Phase 4 | 82 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Dexmedetomidine vs. Midazolam for Facilitating Extubation in Medical and Surgical ICU Patients: A Randomized, Double-Blind Study[NCT00744380] | 23 participants (Actual) | Interventional | 2008-08-31 | Completed | |||
| Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder[NCT00749203] | Phase 2 | 41 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain Patients[NCT04322968] | Phase 3 | 41 participants (Actual) | Interventional | 2018-01-09 | Completed | ||
| A Single Ketamine Infusion Combined With Music for Suicidal Ideation During a Depressive Episode: A Randomized Open Label Clinical Trial[NCT04658420] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-07-01 | Not yet recruiting | ||
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy[NCT05019885] | Phase 2 | 6 participants (Anticipated) | Interventional | 2022-08-26 | Recruiting | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| Assessing a Combined Ketamine and Online Cognitive Behavioural Therapy Intervention for Treatment Resistant Post-Traumatic Stress Disorder[NCT04771767] | Phase 2 | 16 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| The Effect of Therapeutic Ketamine Infusions on the Symptoms of Post-Traumatic Stress Disorder in Combat Veterans[NCT03088384] | 30 participants (Actual) | Observational | 2016-11-28 | Completed | |||
| Evaluation of Mirus™ for Sedation in Resuscitation[NCT02889055] | 9 participants (Actual) | Observational | 2016-01-17 | Terminated (stopped due to Safety profile was not satisfying with sevolflurane) | |||
| A Phase 3, Multicenter, Randomized, Controlled, Open Label, Assessor-Blinded Study to Evaluate the Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensi[NCT05327296] | Phase 3 | 235 participants (Anticipated) | Interventional | 2022-06-30 | Recruiting | ||
| A Phase 3, Multicenter, Randomized, Controlled, Open Label, Assessor-Blinded Study to Evaluate the Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensi[NCT05312385] | Phase 3 | 235 participants (Anticipated) | Interventional | 2022-04-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in suicidal ideation in depressed patients with moderate to severe suicidal thoughts from the pre-infusion baseline to 24 hours after the infusion with ketamine or midazolam, a sedative not known to reduce suicidal ideation, measured with Beck Scale for Suicidal Ideation - clinician rated version. This scale has 19 items scaled 0 (least severe) to 2 (most severe) and a potential score ranging from 0 to 38, with higher score indicating greater severity. (NCT01700829)
Timeframe: Day 1 (24 hours) post-treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Midazolam | -3.66 |
| Ketamine | -8.62 |
The average Z-scores reported below are the average of the Z-scores for all tests administered. The Z-scores for each test were based on published normative data and normative data available in our laboratory. The population mean for a Z-score is zero, with a SD of 1, thus scores below zero would indicate performance below the population norm; a score close to zero indicates performance close to the population norm (or a normalizing of performance). (NCT01700829)
Timeframe: Baseline and Day 1
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Pre-infusion overall neuropsych performance | Day1 post-infusion overall neuropsych performance | |
| Ketamine | -0.306 | -0.01 |
| Midazolam | -0.252 | -0.146 |
"On the mornings of an infusion day and on post-treatment day1, participants used salivettes (Sarstedt AG & Co.) to provide saliva samples upon awakening (Cort1) and 30 minutes later (Cort2) to measure cortisol awakening response (CAR) = (Cort2 - Cort1).~Differences between the midazolam and ketamine groups were tested using an analysis of covariance (ANCOVA) model of the change in CAR from baseline to day1, with treatment group and baseline measurement of the outcome variable as predictors.~Range from 0.1 to 12.5 ng/ml and lower means less stress response, higher means greater stress response." (NCT01700829)
Timeframe: Cort2 - Cort1 = (Day 1 30-mins post-awakening cortisol) - (Day 1 awakening cortisol)
| Intervention | log(ng/mL) (Mean) | |||
|---|---|---|---|---|
| Baseline awakening | Baseline 30 mins post-awakening | Day1 awakening | Day1 30 minutes post-awakening | |
| Ketamine | 0.47 | 0.88 | 0.74 | 1.06 |
| Midazolam | 0.94 | 1.29 | 0.77 | 1.19 |
(NCT00744380)
Timeframe: Duration of ICU stay, up to 24 weeks
| Intervention | days (Median) |
|---|---|
| Midazolam | 3 |
| Dexmedetomidine | 3.5 |
"The ICU-SEQ assesses patient recall of their ICU experience. The ICU-SEQ assesses both psychological (e.g. fearfulness, anxiety) and physical (e.g. pain, difficulty breathing) perceptions of ICU patients who have received mechanical ventilation. It consists of 29 potentially stressful experiences with seven items specifically addressing the endotracheal tube. The extent that patients are bothered by each item is scored on a five point scale: 0 = not at all, 1 = a little bit, 2 = moderately, 3 = quite a bit, and 4 = extremely. The cumulative score is an integer interpreted as interval data with higher scores indicating greater stressful experiences associated with the ICU. The minimum score is 0 and the maximum score possible is 116." (NCT00744380)
Timeframe: Duration of hospital stay, up to 24 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Midazolam | 8.5 |
| Dexmedetomidine | 18.5 |
"The IES-R evaluates subjective distress caused by traumatic events and assesses manifestations of post-traumatic stress disorder (PTSD) or acute stress disorder. It is not diagnostic but possesses excellent reliability and validity for manifestations of PTSD. The IES-R has three subscales (eight items on intrusion, eight items on avoidance, and six items on hyperarousal). Each item is scored on a four point scale: 0 = not at all, 1 = a little bit, 2 = moderately often, 3 = quite a bit, and 4 = extremely often. The total score of each subscale may be averaged and a cumulative score of 30 is indicative of the presence of PTSD. The maximum score for each subscale is 32 for intrusion, 32 for avoidance, and 24 for hyperarousal. The minimum cumulative score is 0 and the maximum cumulative score possible is 88." (NCT00744380)
Timeframe: Duration of hospital stay, up to 24 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Midazolam | 13 |
| Dexmedetomidine | 36 |
(NCT00744380)
Timeframe: Duration of ICU stay, for up to 24 weeks
| Intervention | days (Median) |
|---|---|
| Midazolam | 2.9 |
| Dexmedetomidine | 3.4 |
(NCT00744380)
Timeframe: Duration of ICU stay, for up to 24 weeks
| Intervention | mg (Median) | ||
|---|---|---|---|
| Open-label midazolam while on study drug | All midazolam whil eon study drug | All fentanyl while on study drug | |
| Dexmedetomidine | 65.3 | 65.3 | 4.1 |
| Midazolam | 29 | 126.9 | 5.4 |
The HADS consists of 14 questions, seven for anxiety and seven for depression. Each item is scored from 0 to 3, with a cut-off cumulative score of 11 for both subscales indicative of anxiety or depression. This scoring tool has been used for 30 years, possesses excellent reliability and validity, and avoids reliance conditions that are also common somatic symptoms of illness such fatigue, insomnia, and hypersomnia. The maximum score for each subscale is 21 with a maximum possible cumulative score of 42. The minimum score for each subscale is 0. The minimum cumulative score is 0 (NCT00744380)
Timeframe: Duration of hospital stay, up to 24 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Anxiety | Depression | |
| Dexmedetomidine | 6 | 4 |
| Midazolam | 3 | 6 |
(NCT00744380)
Timeframe: Duration of ICU stay, up to 24 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Hypotension | Bradycardia | Tachycardia | Delirium, new onset | |
| Dexmedetomidine | 10 | 7 | 7 | 1 |
| Midazolam | 6 | 7 | 5 | 5 |
The Riker sedation-agitation score (range 1-7) and PABS (range 0-10) are assessed hourly by the bedside nurse. Riker scores assess restlessness and cooperation. Riker scores of 5 - 7 indicate agitation, 3 - 4 represent adequate sedation and 1 - 2 represent excessive sedation. PABS assessments include domains of restlessness, muscle tone, vocalization, consolability, and facial expressions. PABS assessments of 0 represent no pain, 1 - 3 represent mild pain, 4 - 6 represent moderate pain, and ≥ 7 represent severe pain. (NCT00744380)
Timeframe: Duration of ICU stay, for up to 24 weeks
| Intervention | percentage of assessments while on study (Number) | |||
|---|---|---|---|---|
| Riker score 1-2 while on study drug | Riker score 3-4 while on study drug | Riker score 5-7 while on study drug | Pain score > 3 while on study drug | |
| Dexmedetomidine | 4.1 | 71.2 | 27.1 | 21.4 |
| Midazolam | 5.4 | 84.1 | 6.6 | 13.3 |
Clinician-administered structured interview measuring PTSD symptoms. frequency score - scale 0 = none of the time to 4 = most or all of the time intensity score - scale 0 = none to 4 = extreme To meet criteria for a symptom, a patient must meet criteria in both frequency and intensity score for each item. Frequency and intensity and then combined to form a single severity score. 30 questions scale, with total score ranging from 0 to 240. (NCT00749203)
Timeframe: 7 days after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 54 |
| Midazolam | 65.69 |
"A 22-item self-report questionnaire measuring PTSD symptoms. Items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score ranging from 0 (not at all) to 88 (extremely)" (NCT00749203)
Timeframe: 7 days after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 25.76 |
| Midazolam | 36.32 |
Clinician-administered questionnaire measuring depressive symptoms. The MADRS-S has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression). Mean difference between baseline and 2 weeks. (NCT00749203)
Timeframe: 24 hours after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 12.6 |
| Midazolam | 10.1 |
Self-report questionnaire measuring depressive symptoms. Each item is rated 0 (no depression) to 3 (severe depression). The total score ranges from 0-27. (NCT00749203)
Timeframe: 24 hours after first infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 12.4 |
| Midazolam | 11.3 |
"Severity of PTSD symptoms; items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms" (NCT04322968)
Timeframe: 1 week post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 28.22 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 33.66666667 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 11.44 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 13.41 |
"Severity of PTSD symptoms; items are rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms" (NCT04322968)
Timeframe: 24 hrs post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 36.33333333 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 37 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 10.44444444 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 15.64705882 |
"Severity of chronic pain symptoms; using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the no pain anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity." (NCT04322968)
Timeframe: 1 week post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 48.22 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 52.88 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 43.33 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 48.23 |
"Severity of chronic pain symptoms; using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the no pain anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity." (NCT04322968)
Timeframe: 24 hrs post-infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Chronic Pain With PTSD+IV Ketamine Infusion | 37.22222222 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 49.66666667 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 29.88888889 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 38.70588235 |
"Severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week; No scoring algorithm, but worst pain or the arithmetic mean of the four severity items can be used as measures of pain severity (a range of 0-10, with 10 being worse scores); the arithmetic mean of the seven interference items can be used as a measure of pain interference (a range of 0-10, with 10 being worse scores). The total score is reported for severity items and interference items, which range from 0-40 and 0-70, respectively. Higher values represent worse outcome." (NCT04322968)
Timeframe: 1 week post-infusion
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Pain interference Scale | Pain severity Scale | |
| Chronic Pain With PTSD+IV Ketamine Infusion | 38.62 | 20.75 |
| Chronic Pain With PTSD+IV Ketorolac Infusion | 25.66 | 14.66 |
| Chronic Pain Without PTSD+IV Ketamine Infusion | 9.62 | 12.75 |
| Chronic Pain Without PTSD+IV Ketorolac Infusion | 28.33 | 22.66 |
1 review available for midazolam and Depression
| Article | Year |
|---|---|
Different regimens of intravenous sedatives or hypnotics for electroconvulsive therapy (ECT) in adult patients with depression.
Topics: Adult; Anesthetics, Intravenous; Depression; Electroconvulsive Therapy; Epilepsy, Tonic-Clonic; Etom | 2014 |
13 trials available for midazolam and Depression
| Article | Year |
|---|---|
Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation.
Topics: Adult; Anesthetics, Intravenous; Cognition; Depression; Female; Humans; Ketamine; Male; Midazolam; N | 2021 |
Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Suicidal Ideation | 2022 |
The Relationship Between Acute Dissociative Effects Induced by Ketamine and Treatment Response in Adolescent Patients with Treatment-Resistant Depression.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Depressive | 2023 |
A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2023 |
Changes in symptoms of anxiety, depression, and PTSD in an RCT-study of dentist-administered treatment of dental anxiety.
Topics: Anxiety; Dental Anxiety; Dentists; Depression; Humans; Midazolam; Professional Role; Stress Disorder | 2023 |
Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resist | 2023 |
Study protocol for Ketamine as an adjunctive therapy for major depression (2): a randomised controlled trial (KARMA-Dep [2]).
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Q | 2023 |
A randomized, double-blind pilot study of dexmedetomidine versus midazolam for intensive care unit sedation: patient recall of their experiences and short-term psychological outcomes.
Topics: Adult; Aged; Anxiety; Conscious Sedation; Critical Care; Depression; Dexmedetomidine; Double-Blind M | 2015 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Anxiety Agents; Chronic Disease; Cross-Over Studies; Depres | 2014 |
Ketamine rapidly relieves acute suicidal ideation in cancer patients: a randomized controlled clinical trial.
Topics: Adult; Antidepressive Agents; Depression; Female; Humans; Ketamine; Male; Midazolam; Middle Aged; Ne | 2017 |
Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Cognition Disorders; Conscious Sedation; Delusions; Depress | 2008 |
Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Cognition Disorders; Conscious Sedation; Delusions; Depress | 2008 |
Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Cognition Disorders; Conscious Sedation; Delusions; Depress | 2008 |
Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Cognition Disorders; Conscious Sedation; Delusions; Depress | 2008 |
Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Cognition Disorders; Conscious Sedation; Delusions; Depress | 2008 |
Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Cognition Disorders; Conscious Sedation; Delusions; Depress | 2008 |
Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Cognition Disorders; Conscious Sedation; Delusions; Depress | 2008 |
Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Cognition Disorders; Conscious Sedation; Delusions; Depress | 2008 |
Short- and long-term follow-up of intensive care unit patients after sedation with isoflurane and midazolam--a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Cognition Disorders; Conscious Sedation; Delusions; Depress | 2008 |
Overnight sedation with midazolam or propofol in the ICU: effects on sleep quality, anxiety and depression.
Topics: Adult; Aged; Anxiety; Critical Care; Depression; Female; Hemodynamics; Humans; Hypnotics and Sedativ | 1996 |
Self-administration of midazolam for postoperative anxiety: a double blinded study.
Topics: Adult; Aged; Anxiety; Depression; Double-Blind Method; Female; Humans; Midazolam; Middle Aged; Morph | 1992 |
8 other studies available for midazolam and Depression
| Article | Year |
|---|---|
A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine.
Topics: Anhedonia; Data Analysis; Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Place | 2022 |
The Future of Ketamine in the Treatment of Teen Depression.
Topics: Adolescent; Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ket | 2021 |
Ketamine: Quo Vadis?
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Midazolam; Suicidal Ideation | 2018 |
[Change of hepatic drug metabolism enzymes in rat depression model with kidney-yang deficiency].
Topics: Animals; Chlorzoxazone; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Depression; Dextrome | 2017 |
Evaluation of the anxiolytic and antidepressant effects of asiatic acid, a compound from Gotu kola or Centella asiatica, in the male Sprague Dawley rat.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Centella; Depression; Disease Models, | 2015 |
[Study of change in activity of hepatic drug metabolism enzymes in rat model of chronic unpredictable mild stress].
Topics: Animals; Chlorzoxazone; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Depression; Dextrome | 2015 |
Look again at psychedelic drugs.
Topics: Anxiety; Delirium; Depression; Diazepam; Hallucinogens; Haloperidol; Humans; Lorazepam; Midazolam; P | 2016 |
Sedation in the ICU.
Topics: Academic Dissertations as Topic; Acute Kidney Injury; Aged; Anxiety; Critical Care; Deep Sedation; D | 2012 |